Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668161 | 0.89 | OPRD1 (0.64) | OPRD1OPRM1OPRK1CTSBQRFPR | |
| SCHEMBL29904057 | 0.89 | OPRD1 (0.66) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29904036 | 0.88 | TFPI (0.51) | OPRD1OPRM1OPRK1CTSBQRFPR | |
| SCHEMBL29540560 | 0.87 | OPRM1 (0.59) | OPRD1OPRM1OPRK1CTSB | |
| SCHEMBL31257045 | 0.87 | OPRM1 (0.56) | OPRD1OPRM1OPRK1OPRL1 | |
| SCHEMBL29658158 | 0.87 | MME (0.50) | OPRD1OPRM1CTSB | |
| SCHEMBL29914576 | 0.87 | TFPI (0.50) | OPRD1OPRM1OPRK1CTSBQRFPR | |
| SCHEMBL31257069 | 0.87 | OPRD1 (0.57) | OPRD1OPRM1OPRK1OPRL1 | |
| SCHEMBL31257978 | 0.86 | OPRD1 (0.57) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29512270 | 0.86 | APC (0.55) | OPRD1OPRM1OPRK1QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111200976-B | Radioactive liquid embolism | 微仙美国有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | disclosed |
| US-11992575-B2 | Radioactive liquid embolic | MICROVENTION, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240108781-A1 | POLYMERIC TREATMENT COMPOSITIONS | MICROVENTION, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11801326-B2 | Polymeric treatment compositions | MICROVENTION, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| CN-111200976-B | Radioactive liquid embolism | 微仙美国有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4121130-A1 | LIQUID EMBOLICS | MicroVention, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115279427-A | Liquid embolus | 微仙美国有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220273825-A1 | RADIOPAQUE PARTICLE COMPOSITIONS AND USES THEREOF | GUSTAVE ROUSSY TRANSFERT (FR) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | PDGFRB, ERBB2, AKT1 | OPRD1 2334/4885OPRM1 1480/4885OPRK1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.